Melinda Hajdú

Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study

Ágnes Márk, Melinda Hajdú, Zsófia Váradi et al. · BMC Cancer · 2013 · 39 citations · Full text

Medicine, Oncology, Pharmacology +14

mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression

T. Sticz, Anna Molnár, Ágnes Márk et al. · Journal of Clinical Pathology · 2016 · 20 citations

Medicine, Cancer Biology, Oncology +17

Expression of TGFβ1 and Its Signaling Components by Peripheral Lymphocytes in Systemic Lupus Erythematosus

Eszter Kohut, Melinda Hajdú, P Gergely et al. · Pathology & Oncology Research · 2008 · 16 citations

Life Sciences, Cell Biology, Immunology +14

In Situ Metabolic Characterisation of Breast Cancer and Its Potential Impact on Therapy

Gábor Petővári, Titanilla Dankó, Anna‐Mária Tõkés et al. · Cancers · 2020 · 15 citations · Full text

Medicine, Cancer Biology, Oncology +17

Activity of the Notch‐signalling Pathway in Circulating Human Chronic Lymphocytic Leukaemia Cells

Melinda Hajdú, Anna Sebestyén, Gábor Barna et al. · Scandinavian Journal of Immunology · 2007 · 13 citations

Life Sciences, Cell Biology, Hematology +13